National Diabetes Information Clearinghouse. National diabetes statistics. Available at: http://diabetes.niddk.nih.gov/dm/pubs/statistics/. Accessed September 1, 2005.
2.
International Diabetes Federation. Diabetes atlas. Available at: http://www.eatlas.idf.org/prevalence/. Accessed September 1, 2005.
3.
Sullivan PW, Morrato EH, Ghushchyan V, Wyatt HR, Hill JO. Obesity, inactivity, and the prevalence of diabetes and diabetesrelated cardiovascular comorbidities in the US, 2000-2002. Diabetes Care. 2005;28:1599-1603.
4.
Ogden CL, Flegal KM, Carroll MD, Johnson CL. Prevalence and trends in overweight among US children and adolescents, 1999-2000. JAMA. 2002;288:1728-1732.
5.
Pinhas-Hamiel O, Zeitler P. The global spread of type 2 diabetes mellitus in children and adolescents. J Pediatr.2005;146:693-700.
6.
Gungor N, Thompson R, Sutton-Tyrell K, Janosky J, Arslanian S. Early signs of cardiovascular disease in youth with obesity and type 2 diabetes. Diabetes Care. 2005;28:1219-1221.
7.
Burant CF. Medical Management of Type 2 Diabetes. 5th ed.Alexandria, Va: American Diabetes Association; 2004.
8.
Aronoff SL, Berkowitz K, Schreiner B, Want L. Glucose metabolism and regulation: beyond insulin and glucagon. Diabetes Spectrum. 2004;17:183-190.
9.
Turner RC, Cull CA, Frighi V, Holman RR. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group. JAMA. 1999;281:2005-2012.
10.
Gerich JE. Clinical significance, pathogenesis, and management of postprandial hyperglycemia. Arch Intern Med.2003;163:1306-1316.
11.
Ceriello A, Hanefeld M, Leiter L, et al. Postprandial glucose regulation and diabetic complications. Arch Intern Med.2004;164:2090-2095.
12.
Monnier L, Lapinski H, Colette C. Contributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycemia of type 2 diabetic patients: variations with increasing levels of HbA1c. Diabetes Care. 2003;26:881-885.
13.
Stratton IM, Adler AI, Neil HA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ. 2000;321:405-412.
14.
American Diabetes Association. Standards of medical care in diabetes. Diabetes Care. 2005;28(suppl 1):4-36.
15.
American College of Endocrinology. American College of Endocrinology Consensus Statement on Guidelines for Glycemic Control. Endocr Pract.2002;8(suppl 1):5-11.
16.
International Diabetes Federation Clinical Guidelines Task Force. Global guidelines for type 2 diabetes. Available at: http://www.idf.org/webdata/docs/IDF%20GGT2D.pdf. Accessed September 13, 2005.
17.
Koro CE, Bowlin SJ, Bourgeois N, Fedder DO. Glycemic control from 1988 to 2000 among US adults diagnosed with type 2 diabetes: a preliminary report. Diabetes Care. 2004;27:17-20.
18.
American Association of Clinical Endocrinologists. State of diabetes in America. Available at: http://www.aace.com/pub/StateofDiabetes/DiabetesAmericaReport.pdf. Accessed September 6, 2005.
19.
Heller SR, Colagiuri S, Vaaler S, et al. Hypoglycemia with insulin aspart: a double-blind, randomized, crossover trial in subjects with type 1 diabetes. Diabetic Med.2004;21:769-775.
20.
Garg SK, Gottlieb PA, Hisatomi ME, et al. Improved glycemic control without an increase in severe hypoglycemic episodes in intensively treated patients with type 1 diabetes receiving morning, evening, or split dose insulin glargine. Diabetes Res Clin Pract.2004;66:49-56.
21.
Retnakaran R, Hochman J, DeVries JH, et al. Continuous subcutaneous insulin infusion versus multiple daily injections: the impact of baseline A1C. Diabetes Care. 2004;27:2590-2596.
22.
Nichols GA, Gomez A. Weight changes associated with antihyperglycemic therapies for type 2 diabetes [abstract]. Diabetes. 2005;54(suppl 1):A4-A4. Abstract 13-OR.
23.
Geelhoed-Duijvestijn PHLM, Peyrot M, Matthews DR, et al. Physician resistance to prescribing insulin: an international study [abstract]. Diabetologia. 2003;46(suppl 2):A274-A275. Abstract 793.
24.
Greaves CJ, Brown P, Terry RT, Eiser C, Lings P, Stead JW. Converting to insulin in primary care: an exploration of the needs of practice nurses. J Adv Nurs.2003;42:487-496.
25.
Korytkowski M. When oral agents fail: practical barriers to starting insulin. Int J Obes Relat Metab Disord.2002;26(suppl 3):S18-S24.
26.
Brown J, Nichols G. The glycemic burden of oral agent failure in type 2 diabetes [abstract]. Diabetes. 2003;52(suppl 1):A61-A62. Abstract 264-OR.
27.
Shah BR, Hux JE, Laupacis A, Zinman B, van Walraven C. Clinical inertia in response to inadequate glycemic control: do specialists differ from primary care physicians?Diabetes Care. 2005;28:600-606.
28.
American Diabetes Association. Diabetes. 2005;54(suppl 1).
29.
McIntyre N, Turner DS, Holdsworth CD. New interpretation of oral glucose tolerance. Lancet. 1964;41:20-21.
30.
Elrick H, Stimmler L, Hlad CJ, Arai Y. Plasma insulin responses to oral and intravenous glucose administration. J Clin Endocrinol Metab.1964;24:1076-1082.
31.
Creutzfeldt W, Ebert R. New developments in the incretin concept. Diabetologia. 1985;28:565-573.
32.
Drucker DJ. Enhancing incretin action for the treatment of type 2 diabetes. Diabetes Care. 2003;26:2929-2940.
33.
Deacon CF, Nauck MA, Toft-Nielsen M, Pridal L, Willms B, Holst JJ. Both subcutaneously and intravenously administered glucagon-like peptide I are rapidly degraded from the NH2-terminus in type II diabetic patients and in healthy subjects. Diabetes. 1995;44:1126-1131.
34.
Kreymann B, Williams G, Ghatei MA, Bloom SR. Glucagon-like peptide-1 (7-36): a physiological incretin in man. Lancet. 1987;2:1300-1304.
35.
Komatsu R, Matsuyama T, Namba M, et al. Glucagonostatic and insulinotropic action of glucagon-like peptide I-(7-36)-amide. Diabetes. 1989;38:902-905.
36.
Gutzwiller JP, Goke B, Drewe J, et al. Glucagon-like peptide-1: a potent regulator of food intake in humans. Gut.1999;44:81-86.
37.
Vilsboll T, Holst JJ. Incretins, insulin secretion and type 2 diabetes mellitus. Diabetologia. 2004;47:357-366.
38.
Nauck M, Stockmann F, Ebert R, Creutzfeldt W. Reduced incretin effect in type 2 (non–insulin-dependent) diabetes. Diabetologia. 1986;29:46-52.
39.
Vilsboll T, Krarup T, Deacon CF, Madsbad S, Holst JJ. Reduced postprandial concentrations of intact biologically active glucagon-like peptide 1 in type 2 diabetic patients. Diabetes. 2001;50:609-613.
40.
Rachman J, Barrow BA, Levy JC, Turner RC. Near-normalisation of diurnal glucose concentrations by continuous administration of glucagon-like peptide-1 (GLP-1) in subjects with NIDDM. Diabetologia. 1997;40:205-211.
41.
Nauck MA, Kleine N, Ørskov C, Holst JJ, Willms B, Creutzfeldt W. Normalization of fasting hyperglycemia by exogenous glucagon-like peptide 1 (7-36 amide) in type 2 (non–insulindependent) diabetic patients. Diabetologia. 1993;36:741-744.
42.
Zander M, Madsbad S, Madsen JL, Holst JJ. Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: a parallelgroup study. Lancet. 2002;359:824-830.
43.
Farilla L, Hui H, Bertolotto C, et al. Glucagon-like peptide-1 promotes islet cell growth and inhibits apoptosis in Zucker diabetic rats. Endocrinology. 2002;143:4397-4408.
44.
Farilla L, Bulotta A, Hirshberg B, et al. Glucagon-like peptide 1 inhibits cell apoptosis and improves glucose responsiveness of freshly isolated human islets. Endocrinology. 2003;144:5149-5158.
45.
Degn KB, Juhl CB, Sturis J, et al. One week’s treatment with the long-acting glucagon-like peptide 1 derivative liraglutide (NN2211) markedly improves 24-h glycemia and β- and β-cell function and reduces endogenous glucose release in patients with type 2 diabetes. Diabetes. 2004;53:1187-1194.
